AIM ImmunoTech reports positive DURIPANC progress
Analysis based on 15 articles · First reported Jun 01, 2026 · Last updated Jun 08, 2026
The positive interim clinical progress and ahead-of-schedule enrollment in the DURIPANC study are likely to positively impact the stock price and investor confidence in AIM ImmunoTech. This advancement in pancreatic cancer treatment could also have a broader positive effect on the pharmaceutical and biotechnology industries, particularly for companies involved in oncology research.
AIM ImmunoTech Inc. reported positive mid-year interim clinical progress from its Phase 2 DURIPANC study, evaluating Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. The company also announced the ahead-of-schedule enrollment of the final patient, surpassing its original July 2026 target. AIM ImmunoTech remains on track for a December 2026 evaluation of the study's primary endpoint, Clinical Benefit Rate. The DURIPANC study is a collaboration between AIM ImmunoTech, AstraZeneca, and Erasmus MC. This progress supports AIM ImmunoTech's plans for a pivotal Phase 3 clinical trial and aims to address the critical unmet need for more effective and less toxic treatments for pancreatic cancer patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard